ARBUTUS BIOPHARMA CORP. REGISTERED SHARES O.N. ehem Tekmira Pharmaceuticals vor dem Durchbruch? (Seite 692)
eröffnet am 07.08.14 10:02:11 von
neuester Beitrag 24.04.24 15:51:26 von
neuester Beitrag 24.04.24 15:51:26 von
Beiträge: 10.978
ID: 1.197.187
ID: 1.197.187
Aufrufe heute: 105
Gesamt: 1.133.567
Gesamt: 1.133.567
Aktive User: 3
ISIN: CA03879J1003 · WKN: A14XMD · Symbol: ABUS
2,5400
EUR
-1,01 %
-0,0260 EUR
Letzter Kurs 12:29:03 Tradegate
Neuigkeiten
18.04.24 · globenewswire  |
10.04.24 · wO Chartvergleich |
04.04.24 · globenewswire |
08.03.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 53,75 | +99,07 | |
| 1,9000 | +59,66 | |
| 0,5140 | +34,91 | |
| 6,0500 | +32,39 | |
| 1,3500 | +29,82 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,6900 | -10,82 | |
| 3,4000 | -13,92 | |
| 0,7603 | -15,56 | |
| 5,2050 | -33,27 | |
| 9,5450 | -34,22 |
Beitrag zu dieser Diskussion schreiben
Feedback
http://www.sueddeutsche.de/gesundheit/ebola-fall-in-grossbri…
Infizierte Helferin konnte ungehindert einreisen.
Die Behörden sind noch auf der Suche nach mehr als 100 Passagieren, die auf mehreren Flügen im Umfeld der erkrankten Schottin saßen.In zwei weiteren Ebola-Verdachtsfällen
in Großbritannien wird das Ergebnis erwartet.
Schottin konnte einreisen, obwohl sie selbst Ansteckung befürchtete.
Infizierte Helferin konnte ungehindert einreisen.
Die Behörden sind noch auf der Suche nach mehr als 100 Passagieren, die auf mehreren Flügen im Umfeld der erkrankten Schottin saßen.In zwei weiteren Ebola-Verdachtsfällen
in Großbritannien wird das Ergebnis erwartet.
Schottin konnte einreisen, obwohl sie selbst Ansteckung befürchtete.
Das waren fantastische News zum Jahreswechsel!!
Ich wünsche alle einen guten Start in einem gesunden und erfolgreichen Jahr 2015!
Viele Schneegrüsse aus 2000 m Höhe bei sternenklarem Himmel
Ich wünsche alle einen guten Start in einem gesunden und erfolgreichen Jahr 2015!
Viele Schneegrüsse aus 2000 m Höhe bei sternenklarem Himmel
Also wenn das stimmt, könnte es wieder nach oben gehen! Bevor wieder jeder meckert, dass die Quelle von der dummen Bild kommt bitte googeln. Kann man auch auf englisch finden, etc.
http://www.bild.de/politik/ausland/isis/isis-mit-ebola-infiz…
Hat die todbringende Seuche Ebola jetzt die Terror-Miliz ISIS erreicht? Arabische Medien berichten, dass in der irakischen Stadt Mossul zwei Ebola-Erkrankungen gemeldet wurden!
„Viele Einwohner von Mossul haben sich mit eingeschleppten Krankheiten und Seuchen angesteckt, darunter zwei Ebola-Kranke und 26 HIV-Infektionen“, zitiert die irakische Staats-Zeitung „Al-Saba” medizinische Versorgungsstellen in Mossul. „Diese Krankheiten wurden von Terroristen und Auswanderern aus verschiedenen Ländern, besonders Afrika, nach Mossul eingeschleppt. Die irakische Stadt, gut 400 Kilometer von Baghdad entfernt, wird zu großen Teilen von ISIS kontrolliert.
Erst vor gut einem Monat hatte das irakische Gesundheitsministerium davor gewarnt, dass die Ebola-Seuche durch ISIS-Terroristen in den Irak eingeschleppt werden könne. Nun könnte diese düstere Warnung Realität geworden sein.
#Iraq's daily Sabah: 2 cases of #Ebola virus & 26 cases of #HIV have been registered in #Mosul (#Nineveh #IS #ISIL #ISIS #AIDS)
— Radio Free Iraq (@iraqhurr_eng) December 31, 2014
Wenn sich ISIS-Terroristen mit dem Todes-Virus Ebola anstecken, könnten sie zu einer noch größeren Gefahr werden. Erst im vergangenen Herbst hatte Marc Thiessen, früher Redenschreiber von Ex-US-Präsident George W. Bush, in der „Washington Post“ ein Schreckens-Szenario entworfen und zum Beispiel davor gewarnt, dass sich infizierte Selbstmord-Attentäter an einem belebten Ort – etwa einem Einkaufszentrum – selbst in die Luft sprengen könnten. Ihr virusverseuchtes Blut würde umher spritzten und Dutzende Menschen anstecken.
US-Sicherheits- und Terror-Experte Scott Stewart vom wichtigen Think Tank „Stratfor“ ist allerdings skeptisch. „Zu dem Zeitpunkt, an dem Ebola-Patienten hochansteckend sind, sind sie schon schwerkrank. Sie sind bettlägerig, haben hohes Fieber und Durchfall und müssen sich ständig übergeben. Sie haben keine Kraft mehr, um sich in eine Menschenmenge zu begeben.“ Außerdem würden der Explosionsdruck und die Hitze der Bombe wohl die meisten Viren töten. „Dschihadisten können mit weit weniger Aufwand viel mehr Menschen töten“, sagte Stewart weiter.
Genaue Informationen über den Ausbruch der Seuche in Mossul sind bisher nicht bekannt. Auch wie viele Terroristen tatsächlich angesteckt sind, weiß man noch nicht.
http://www.bild.de/politik/ausland/isis/isis-mit-ebola-infiz…
Hat die todbringende Seuche Ebola jetzt die Terror-Miliz ISIS erreicht? Arabische Medien berichten, dass in der irakischen Stadt Mossul zwei Ebola-Erkrankungen gemeldet wurden!
„Viele Einwohner von Mossul haben sich mit eingeschleppten Krankheiten und Seuchen angesteckt, darunter zwei Ebola-Kranke und 26 HIV-Infektionen“, zitiert die irakische Staats-Zeitung „Al-Saba” medizinische Versorgungsstellen in Mossul. „Diese Krankheiten wurden von Terroristen und Auswanderern aus verschiedenen Ländern, besonders Afrika, nach Mossul eingeschleppt. Die irakische Stadt, gut 400 Kilometer von Baghdad entfernt, wird zu großen Teilen von ISIS kontrolliert.
Erst vor gut einem Monat hatte das irakische Gesundheitsministerium davor gewarnt, dass die Ebola-Seuche durch ISIS-Terroristen in den Irak eingeschleppt werden könne. Nun könnte diese düstere Warnung Realität geworden sein.
#Iraq's daily Sabah: 2 cases of #Ebola virus & 26 cases of #HIV have been registered in #Mosul (#Nineveh #IS #ISIL #ISIS #AIDS)
— Radio Free Iraq (@iraqhurr_eng) December 31, 2014
Wenn sich ISIS-Terroristen mit dem Todes-Virus Ebola anstecken, könnten sie zu einer noch größeren Gefahr werden. Erst im vergangenen Herbst hatte Marc Thiessen, früher Redenschreiber von Ex-US-Präsident George W. Bush, in der „Washington Post“ ein Schreckens-Szenario entworfen und zum Beispiel davor gewarnt, dass sich infizierte Selbstmord-Attentäter an einem belebten Ort – etwa einem Einkaufszentrum – selbst in die Luft sprengen könnten. Ihr virusverseuchtes Blut würde umher spritzten und Dutzende Menschen anstecken.
US-Sicherheits- und Terror-Experte Scott Stewart vom wichtigen Think Tank „Stratfor“ ist allerdings skeptisch. „Zu dem Zeitpunkt, an dem Ebola-Patienten hochansteckend sind, sind sie schon schwerkrank. Sie sind bettlägerig, haben hohes Fieber und Durchfall und müssen sich ständig übergeben. Sie haben keine Kraft mehr, um sich in eine Menschenmenge zu begeben.“ Außerdem würden der Explosionsdruck und die Hitze der Bombe wohl die meisten Viren töten. „Dschihadisten können mit weit weniger Aufwand viel mehr Menschen töten“, sagte Stewart weiter.
Genaue Informationen über den Ausbruch der Seuche in Mossul sind bisher nicht bekannt. Auch wie viele Terroristen tatsächlich angesteckt sind, weiß man noch nicht.
ab Montag nachmittag geht es richtig los.
Antwort auf Beitrag Nr.: 48.672.998 von diamantes am 31.12.14 15:45:21bei 20$ ist noch ein Gap offen wäre super wen nwir es schliessen
Trading Spotlight
Antwort auf Beitrag Nr.: 48.672.998 von diamantes am 31.12.14 15:45:21
Tekmira Provides Update on TKM-PLK1 Phase I/II Clinical Study in Patients With Advanced Gastrointestinal Neuroendocrine Tumors and Adrenocortical Carcinoma
Tekmira Pharmaceuticals 38 minutes ago GlobeNewswire
VANCOUVER, British Columbia, Dec. 31, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (TKMR) (TKM.TO), a leading developer of RNA interference (RNAi) therapeutics, today provided a status update on the Phase I/II clinical study in patients with advanced Gastrointestinal Neuroendocrine Tumors (GI-NET) and Adrenocortical Carcinoma (ACC).
Tekmira today reported that:
Enrolment of the target patient numbers in these Phase I/II studies has been completed;
To date, 55 patients, in the both the Phase I and Phase I/II studies have been treated at doses of >= 0.6 mg/kg, considered to be in the efficacious dose range based on preclinical studies. Of these, 31 patients comprise the target population of GI-NET or ACC patients;
Nine GI-NET and ACC patients remain actively on treatment, and data collection is ongoing;
The Company continues to see evidence of anti-tumor activity in some treated subjects, including one ACC patient with an almost complete resolution of their disease;
Final data from these studies is expected in mid-2015.
"Having completed enrolment in these studies, we will follow these patients to measure the responses observed with TKM-PLK1 in patient groups where there are very few, if any, treatment options," said Dr. Mark J. Murray, Tekmira's President and CEO. "We are on track to report complete study results and determine the TKM-PLK1 development path forward next year."
About Gastrointestinal Neuroendocrine Tumors (GI-NET)
Neuroendocrine tumors (NETs) refer to a group of unusual and complex cancers that affect neuroendocrine cells, with those arising in the gastrointestinal tract referred to as GI-NET. A Surveillance Epidemiology and End Results (SEER) database analysis demonstrates a dramatic five-fold increase in the incidence of neuroendocrine tumors from 1973 to 2004. Incidence of GI-NET is predicted to continue to rise at a faster rate than other malignant tumors.
Each year an estimated 8,000 people in the United States are diagnosed with a neuroendocrine tumor that starts in the gastrointestinal tract, which includes the stomach, intestine, appendix, colon, or rectum. There is a poor prognosis for advanced metastatic NETs, with survival rates for GI-NET ranging from five to 56 months. (Source: American Cancer Society, and www.neuroendocrinetumor.com)
About Adrenocortical Carcinoma (ACC)
Adrenocortical Carcinoma is a rare cancer that forms in the outer layer of tissue of the adrenal gland (a small organ on top of each kidney that makes steroid hormones, adrenaline, and noradrenaline to control heart rate, blood pressure, and other body functions). Adult adrenocortical carcinoma tumors are aggressive with a very poor prognosis. Between 60%-70% of patients at the time of diagnosis are found to have stage III or IV disease. These patients have a survival rate of 40%, or less, with a known recurrence rate between 70% and 90%.
As adrenocortical carcinomas are so rare, there has been only limited prospective evaluation of treatment strategies. Very few, if any, universally accepted treatment standards have been identified. (Source:American Cancer Society)
About TKM-PLK1 Phase I/II Clinical Trial Targeting GI-NET/ACC
This ongoing TKM-PLK1 Phase I/II clinical trial is currently targeting two indications: GI-NET and ACC. This trial is a multi-center, single arm, open label study designed to measure efficacy using Response Evaluation Criteria in Solid Tumors and tumor biomarkers for GI-NET patients, as well as to evaluate TKM-PLK1's safety, tolerability and pharmacokinetics. TKM-PLK1, which employs a unique lipid nanoparticle (LNP) formulation for oncology applications, is administered weekly with each four-week cycle consisting of three once-weekly doses followed by a rest week. Tekmira has achieved its target enrolment for the Phase I/II trials of TKM-PLK1.
About RNAi and Tekmira's LNP
RNAi therapeutics have the potential to treat a number of human diseases by "silencing" disease causing genes. The discoverers of RNAi, a gene silencing mechanism used by all cells, were awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi trigger molecules often require delivery technology to be effective as therapeutics. Tekmira believes its LNP technology represents the most advanced and widely adopted delivery technology for the systemic delivery of RNAi triggers. Tekmira's LNP platform is being utilized in multiple clinical trials in various disease areas by Tekmira and its partners. Tekmira's LNP technology (formerly referred to as stable nucleic acid-lipid particles or SNALP) encapsulates RNAi triggers with high efficiency in uniform lipid nanoparticles that are effective in delivering these therapeutic compounds to disease sites. Tekmira's LNP formulations are manufactured by a proprietary method which is robust, scalable and highly reproducible, and LNP-based products have been reviewed by multiple regulatory agencies for use in clinical trials. LNP formulations comprise several lipid components that can be adjusted to suit the specific application.
About Tekmira
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle (LNP) delivery technology to pharmaceutical and biotechnology partners. Tekmira has been working in the field of nucleic acid delivery for over a decade, and has broad intellectual property covering its delivery technology. Further information about Tekmira can be found at www.tekmira.com. Tekmira is based in Vancouver, Canada and Seattle, USA.
Forward-Looking Statements and Information
This news release contains "forward-looking statements" or "forward-looking information" within the meaning of applicable securities laws (collectively, "forward-looking statements"). Forward-looking statements in this news release include statements about Tekmira's strategy, future operations, clinical trials, prospects and the plans of management; RNAi (ribonucleic acid interference) product development programs; and the development of TKM-PLK1 for the treatment of two therapeutic oncology indications: advanced Gastrointestinal Neuroendocrine Tumors (GI-NET) and Adrenocortical Carcinoma (ACC); and a status report of the Phase I/II clinical study with TKM-PLK1 in patients with GI-NET or ACC.
With respect to the forward-looking statements contained in this news release, Tekmira has made numerous assumptions regarding, among other things: LNP's status as a leading RNAi delivery technology. While Tekmira considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.
Additionally, there are known and unknown risk factors which could cause Tekmira's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: TKM-PLK1 may not prove to be effective in the treatment of GI-NET or ACC; complete study results in the second half of 2015, may not generate results that permit advancing the product into further clinical studies; Tekmira's products may not prove to be effective or as potent as currently believed; the FDA may refuse to approve Tekmira's products, or place restrictions on Tekmira's ability to commercialize its products; Tekmira may not obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; Tekmira may face competition from other pharmaceutical or biotechnology companies and the possibility that other organizations have made advancements in RNAi delivery technology that Tekmira is not aware of; anticipated pre-clinical and clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested drug candidate; and economic and capital market conditions.
A more complete discussion of the risks and uncertainties facing Tekmira appears in Tekmira's Annual Report on Form 10-K and Tekmira's continuous disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Tekmira disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
Contact:
Investors
Julie P. Rezler
Director, Investor Relations
Phone: 604-419-3200
Email: jrezler@tekmira.com
Media
Please direct all media inquiries to media@tekmira.com
View Comments (0)
Share this
Recommended for You
New Biotech ETF Hits the Market
The ALPS Medical Breakthroughs ETF debuted on the market Wednesday and is focused on research and development opportunities in biotechnology and pharmaceutical industries.
24/7 Wall St.
KFZ-Werkzeuge stark reduziert
Jetzt online bei Zoro Tools bestellen und Rabatt auf professionelles KFZ-Werkzeug von KNIPEX, Aerotec oder Projahn sichern. Nur noch für kurze Zeit!
www.zorotools.deSponsored
Here's The Brilliant Trading Advice 50-Year NYSE Veteran Art Cashin Has For Investors
UBS's Art Cashin rang the opening bell on the...
Business Insider
Credit Suisse’s Top 4 Focus List Stock Picks for 2015
Credit Suisse updated its U.S. Focus List right before Christmas, and this is effectively the firm's highest conviction list for the year ahead.
24/7 Wall St.
CS $25.35 0.16%
Jim Cramer's going gold with your portfolio
Jim Cramer thinks it is not a matter if you want to buy gold-you need it. Here's the best way to buy gold and keep your portfolio safe.
CNBC
6 Brands That May Not Make It Through 2015
Profits after taxes surged to all-time highs — as did the stock market — while familiar names like Facebook, Amazon, Disney and many others have seen strong growth in their brand valuations.
The Fiscal Times
RSH $0.39 0.10%
Boost Your Personal Brand With an MBA Programme
Potential to double your salary in 5 years! Study in Vancouver, voted as the 3rd most liveable city in the World by The Economist. Get more info now!
Perfect-MBASponsored
Upcoming NYSE, Nasdaq Stock Market Holidays For 2015
U.S. markets will be open for a full day Wednesday. But the Nasdaq and New York Stock Exchange will be closed on Thursday in observance of New Year's Day and reopen Friday Jan. 2 for the first day of trading ...
Investor's Business Daily
^IXCO 2,485.10 0.17%
Ugly Ducklings Sprint and AMD Are Poised to Become Swans in 2015
Investors are scrambling to find 2015's version of BlackBerry. Sprint and Advanced Micro Devices are good candidates.
TheStreet.com
4 Losing stocks to buy for 2015
The "Fast Money" traders give four losing trades that are poised for success in 2015.
CNBC Videos
Special Report: The mainland's colonization of the Hong Kong economy
HONG KONG (Reuters) - When Xi Jinping wanted to deliver a political message to Hong Kong as protesters demanding free elections were threatening to take to the streets, he summoned the tycoons who dominate the city’s economy. The words from the Chinese leader at the September 22 meeting in Beijing…
Reuters
Brain Training Games
Challenge your brain with games from Lumosity.com, the personal trainer for your brain.
LumositySponsored
Here Are the Steel Stocks Investors Should Buy for Big Gains in 2015
Steel companies have been shunned by investors, but these two steel stocks can still deliver in 2015.
TheStreet.com
NUE $49.36 -0.31%
Play
U.S. is in an oil war with Russia and OPEC: Katusa
Oversupply and slowing consumption have resulted in oil falling to its cheapest price since May of 2009. OPEC, Russia and shale head into 2015 looking to stake out a bigger share of the market.
Yahoo Finance
Seadrill (SDRL) Stock Gains Following Deepwater Vessel Purchase
Seadrill (SDRL) shares benefited from the $456 million purchase of a deepwater drilling vessel as well as rising oil prices.
TheStreet.com
SDRL $11.72 -1.76%
IBM is doing something no Dow stock has done since 1995
For the second year in a row, shares of Big Blue are in the red. But for those looking for a rebound in 2015, some industry watchers have a simple message: don’t hold your breath.
Talking Numbers
^DJI 18,019.00 0.20%
Screener.co Global Equity Research Platform
Screen for stocks that match your fundamentals-based investment strategy with our advanced global equity research platform.
AdChoicesScreener.coSponsored
Play
Thousands protest in Moscow
Thousands are involved in an unauthorized protest in Moscow. Details, with CNBC's Simon Hobbs.
CNBC Videos
The Single Most Important Thing You Need to Know About Credit Scores
There's a lot to know about credit scores, but if there's one crucial thing a lot of people don't understand, it is this fact.
Credit.com
Retirement: Is the 4% rule still relevant?
Is the 4% rule, which has guiding financial plans for years, still relevant for retirees?
USA TODAY
Bank on bigger dividends in this sector next year
Yield-hungry investors take note: The financial services sector led by big banks is expected to become the dividend growth leader next year.
CNBC
BAC $18.13 0.00%
Is Your Mac Slowing You Down And Driving You Nuts?
Clean Up, Speed Up & Optimize Your Mac In Just 2 Clicks.
Detox My MacSponsored
Gold will sink to just 3 digits: Sullivan predicts
CNBC's Brian Sullivan looks toward 2015 and shares predictions on gold, the Dow, IBM and more.
CNBC
Pacific Ethanol to buy Aventine for $190 million in stock
Deal would make company the fifth-largest ethanol producer in the U.S.
MarketWatch31 mins ago
Lockheed Wins F-22 Modification Contract Worth $67.8M - Analyst Blog
Lockheed Martin (LMT) won a modification contract worth $67.8 million from the U.S. Air Force for providing services on the F-22 aircraft.
Zacks
LMT $195.22 -0.11%
Press Releases
Tekmira Establishes Manufacturing and Clinical Trial Agreement to Provide TKM-Ebola-Guinea for Clinical Studies in West Africa
Tekmira Receives Clearance to Conduct a Phase I Clinical Study With TKM-HBV
Tekmira Pharmaceuticals Announces Leadership Changes
More Press Release for Tekmira Pharmaceuticals Corporation
Related Quotes
TKM.TO17.32+7.51%
Tekmira Pharmaceuticals Corpor … Watchlist
17.32+1.21(7.51%)
Toronto9:53 AM EST
Tekmira gains on UK Ebola case
Financial Times q 20 hrs ago
Tekmira to supply Ebola treatment for studies in West Africa
Reuters 8 days ago
More
KFZ-Werkzeuge stark reduziert!
Sponsored www.zorotools.de
Rates
Must Reads
Yahoo Finance
3 key questions for McDonald's in 2015
Yahoo Finance
Apple wins Christmas with 51% of new device activations
Yahoo Finance
College to get cheaper for middle-class families
Yahoo Finance
The iPhone mafia: What happens to your stolen smartphone
Yahoo Finance
The biggest surprise for tech investors in 2014 won't come again next year
Hot Stock Minute
Will investors love Shake Shack...or shake it off?
Yahoo Finance
Should you buy Facebook?
Talking Numbers
IBM is doing something no Dow stock has done since 1995
More Top News »
More Market News
Markets in Review: Winners and Losers in 2014
Art Cashin's year-end market message CNBC Videos
North Dakota Town 'dodged A Bullet' In Crude Explosion, …
Amazon Reigns Supreme in E-Commerce as New Competitors …
Poll
With the Nasdaq about 5% away from all-time highs, which sector is best poised to lead the way higher?
28 days remaining
Healthcare
Tech
Energy
See Results
Copyright © 2014 <a href="http://www.globenewswire.com/">GlobeNewswire</a>. All rights reserved. Redistribution of this content is expressly prohibited without prior written consent. GlobeNewswire makes no claims concerning the accuracy or validity of the information, and shall not be held liable for any errors, delays, omissions or use thereof.
Data Disclaimer
Help / Suggestions
Privacy
About Our Ads
Terms
newsss
Tekmira Provides Update on TKM-PLK1 Phase I/II Clinical Study in Patients With Advanced Gastrointestinal Neuroendocrine Tumors and Adrenocortical Carcinoma
Tekmira Pharmaceuticals 38 minutes ago GlobeNewswire
VANCOUVER, British Columbia, Dec. 31, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (TKMR) (TKM.TO), a leading developer of RNA interference (RNAi) therapeutics, today provided a status update on the Phase I/II clinical study in patients with advanced Gastrointestinal Neuroendocrine Tumors (GI-NET) and Adrenocortical Carcinoma (ACC).
Tekmira today reported that:
Enrolment of the target patient numbers in these Phase I/II studies has been completed;
To date, 55 patients, in the both the Phase I and Phase I/II studies have been treated at doses of >= 0.6 mg/kg, considered to be in the efficacious dose range based on preclinical studies. Of these, 31 patients comprise the target population of GI-NET or ACC patients;
Nine GI-NET and ACC patients remain actively on treatment, and data collection is ongoing;
The Company continues to see evidence of anti-tumor activity in some treated subjects, including one ACC patient with an almost complete resolution of their disease;
Final data from these studies is expected in mid-2015.
"Having completed enrolment in these studies, we will follow these patients to measure the responses observed with TKM-PLK1 in patient groups where there are very few, if any, treatment options," said Dr. Mark J. Murray, Tekmira's President and CEO. "We are on track to report complete study results and determine the TKM-PLK1 development path forward next year."
About Gastrointestinal Neuroendocrine Tumors (GI-NET)
Neuroendocrine tumors (NETs) refer to a group of unusual and complex cancers that affect neuroendocrine cells, with those arising in the gastrointestinal tract referred to as GI-NET. A Surveillance Epidemiology and End Results (SEER) database analysis demonstrates a dramatic five-fold increase in the incidence of neuroendocrine tumors from 1973 to 2004. Incidence of GI-NET is predicted to continue to rise at a faster rate than other malignant tumors.
Each year an estimated 8,000 people in the United States are diagnosed with a neuroendocrine tumor that starts in the gastrointestinal tract, which includes the stomach, intestine, appendix, colon, or rectum. There is a poor prognosis for advanced metastatic NETs, with survival rates for GI-NET ranging from five to 56 months. (Source: American Cancer Society, and www.neuroendocrinetumor.com)
About Adrenocortical Carcinoma (ACC)
Adrenocortical Carcinoma is a rare cancer that forms in the outer layer of tissue of the adrenal gland (a small organ on top of each kidney that makes steroid hormones, adrenaline, and noradrenaline to control heart rate, blood pressure, and other body functions). Adult adrenocortical carcinoma tumors are aggressive with a very poor prognosis. Between 60%-70% of patients at the time of diagnosis are found to have stage III or IV disease. These patients have a survival rate of 40%, or less, with a known recurrence rate between 70% and 90%.
As adrenocortical carcinomas are so rare, there has been only limited prospective evaluation of treatment strategies. Very few, if any, universally accepted treatment standards have been identified. (Source:American Cancer Society)
About TKM-PLK1 Phase I/II Clinical Trial Targeting GI-NET/ACC
This ongoing TKM-PLK1 Phase I/II clinical trial is currently targeting two indications: GI-NET and ACC. This trial is a multi-center, single arm, open label study designed to measure efficacy using Response Evaluation Criteria in Solid Tumors and tumor biomarkers for GI-NET patients, as well as to evaluate TKM-PLK1's safety, tolerability and pharmacokinetics. TKM-PLK1, which employs a unique lipid nanoparticle (LNP) formulation for oncology applications, is administered weekly with each four-week cycle consisting of three once-weekly doses followed by a rest week. Tekmira has achieved its target enrolment for the Phase I/II trials of TKM-PLK1.
About RNAi and Tekmira's LNP
RNAi therapeutics have the potential to treat a number of human diseases by "silencing" disease causing genes. The discoverers of RNAi, a gene silencing mechanism used by all cells, were awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi trigger molecules often require delivery technology to be effective as therapeutics. Tekmira believes its LNP technology represents the most advanced and widely adopted delivery technology for the systemic delivery of RNAi triggers. Tekmira's LNP platform is being utilized in multiple clinical trials in various disease areas by Tekmira and its partners. Tekmira's LNP technology (formerly referred to as stable nucleic acid-lipid particles or SNALP) encapsulates RNAi triggers with high efficiency in uniform lipid nanoparticles that are effective in delivering these therapeutic compounds to disease sites. Tekmira's LNP formulations are manufactured by a proprietary method which is robust, scalable and highly reproducible, and LNP-based products have been reviewed by multiple regulatory agencies for use in clinical trials. LNP formulations comprise several lipid components that can be adjusted to suit the specific application.
About Tekmira
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle (LNP) delivery technology to pharmaceutical and biotechnology partners. Tekmira has been working in the field of nucleic acid delivery for over a decade, and has broad intellectual property covering its delivery technology. Further information about Tekmira can be found at www.tekmira.com. Tekmira is based in Vancouver, Canada and Seattle, USA.
Forward-Looking Statements and Information
This news release contains "forward-looking statements" or "forward-looking information" within the meaning of applicable securities laws (collectively, "forward-looking statements"). Forward-looking statements in this news release include statements about Tekmira's strategy, future operations, clinical trials, prospects and the plans of management; RNAi (ribonucleic acid interference) product development programs; and the development of TKM-PLK1 for the treatment of two therapeutic oncology indications: advanced Gastrointestinal Neuroendocrine Tumors (GI-NET) and Adrenocortical Carcinoma (ACC); and a status report of the Phase I/II clinical study with TKM-PLK1 in patients with GI-NET or ACC.
With respect to the forward-looking statements contained in this news release, Tekmira has made numerous assumptions regarding, among other things: LNP's status as a leading RNAi delivery technology. While Tekmira considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.
Additionally, there are known and unknown risk factors which could cause Tekmira's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: TKM-PLK1 may not prove to be effective in the treatment of GI-NET or ACC; complete study results in the second half of 2015, may not generate results that permit advancing the product into further clinical studies; Tekmira's products may not prove to be effective or as potent as currently believed; the FDA may refuse to approve Tekmira's products, or place restrictions on Tekmira's ability to commercialize its products; Tekmira may not obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; Tekmira may face competition from other pharmaceutical or biotechnology companies and the possibility that other organizations have made advancements in RNAi delivery technology that Tekmira is not aware of; anticipated pre-clinical and clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested drug candidate; and economic and capital market conditions.
A more complete discussion of the risks and uncertainties facing Tekmira appears in Tekmira's Annual Report on Form 10-K and Tekmira's continuous disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Tekmira disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
Contact:
Investors
Julie P. Rezler
Director, Investor Relations
Phone: 604-419-3200
Email: jrezler@tekmira.com
Media
Please direct all media inquiries to media@tekmira.com
View Comments (0)
Share this
Recommended for You
New Biotech ETF Hits the Market
The ALPS Medical Breakthroughs ETF debuted on the market Wednesday and is focused on research and development opportunities in biotechnology and pharmaceutical industries.
24/7 Wall St.
KFZ-Werkzeuge stark reduziert
Jetzt online bei Zoro Tools bestellen und Rabatt auf professionelles KFZ-Werkzeug von KNIPEX, Aerotec oder Projahn sichern. Nur noch für kurze Zeit!
www.zorotools.deSponsored
Here's The Brilliant Trading Advice 50-Year NYSE Veteran Art Cashin Has For Investors
UBS's Art Cashin rang the opening bell on the...
Business Insider
Credit Suisse’s Top 4 Focus List Stock Picks for 2015
Credit Suisse updated its U.S. Focus List right before Christmas, and this is effectively the firm's highest conviction list for the year ahead.
24/7 Wall St.
CS $25.35 0.16%
Jim Cramer's going gold with your portfolio
Jim Cramer thinks it is not a matter if you want to buy gold-you need it. Here's the best way to buy gold and keep your portfolio safe.
CNBC
6 Brands That May Not Make It Through 2015
Profits after taxes surged to all-time highs — as did the stock market — while familiar names like Facebook, Amazon, Disney and many others have seen strong growth in their brand valuations.
The Fiscal Times
RSH $0.39 0.10%
Boost Your Personal Brand With an MBA Programme
Potential to double your salary in 5 years! Study in Vancouver, voted as the 3rd most liveable city in the World by The Economist. Get more info now!
Perfect-MBASponsored
Upcoming NYSE, Nasdaq Stock Market Holidays For 2015
U.S. markets will be open for a full day Wednesday. But the Nasdaq and New York Stock Exchange will be closed on Thursday in observance of New Year's Day and reopen Friday Jan. 2 for the first day of trading ...
Investor's Business Daily
^IXCO 2,485.10 0.17%
Ugly Ducklings Sprint and AMD Are Poised to Become Swans in 2015
Investors are scrambling to find 2015's version of BlackBerry. Sprint and Advanced Micro Devices are good candidates.
TheStreet.com
4 Losing stocks to buy for 2015
The "Fast Money" traders give four losing trades that are poised for success in 2015.
CNBC Videos
Special Report: The mainland's colonization of the Hong Kong economy
HONG KONG (Reuters) - When Xi Jinping wanted to deliver a political message to Hong Kong as protesters demanding free elections were threatening to take to the streets, he summoned the tycoons who dominate the city’s economy. The words from the Chinese leader at the September 22 meeting in Beijing…
Reuters
Brain Training Games
Challenge your brain with games from Lumosity.com, the personal trainer for your brain.
LumositySponsored
Here Are the Steel Stocks Investors Should Buy for Big Gains in 2015
Steel companies have been shunned by investors, but these two steel stocks can still deliver in 2015.
TheStreet.com
NUE $49.36 -0.31%
Play
U.S. is in an oil war with Russia and OPEC: Katusa
Oversupply and slowing consumption have resulted in oil falling to its cheapest price since May of 2009. OPEC, Russia and shale head into 2015 looking to stake out a bigger share of the market.
Yahoo Finance
Seadrill (SDRL) Stock Gains Following Deepwater Vessel Purchase
Seadrill (SDRL) shares benefited from the $456 million purchase of a deepwater drilling vessel as well as rising oil prices.
TheStreet.com
SDRL $11.72 -1.76%
IBM is doing something no Dow stock has done since 1995
For the second year in a row, shares of Big Blue are in the red. But for those looking for a rebound in 2015, some industry watchers have a simple message: don’t hold your breath.
Talking Numbers
^DJI 18,019.00 0.20%
Screener.co Global Equity Research Platform
Screen for stocks that match your fundamentals-based investment strategy with our advanced global equity research platform.
AdChoicesScreener.coSponsored
Play
Thousands protest in Moscow
Thousands are involved in an unauthorized protest in Moscow. Details, with CNBC's Simon Hobbs.
CNBC Videos
The Single Most Important Thing You Need to Know About Credit Scores
There's a lot to know about credit scores, but if there's one crucial thing a lot of people don't understand, it is this fact.
Credit.com
Retirement: Is the 4% rule still relevant?
Is the 4% rule, which has guiding financial plans for years, still relevant for retirees?
USA TODAY
Bank on bigger dividends in this sector next year
Yield-hungry investors take note: The financial services sector led by big banks is expected to become the dividend growth leader next year.
CNBC
BAC $18.13 0.00%
Is Your Mac Slowing You Down And Driving You Nuts?
Clean Up, Speed Up & Optimize Your Mac In Just 2 Clicks.
Detox My MacSponsored
Gold will sink to just 3 digits: Sullivan predicts
CNBC's Brian Sullivan looks toward 2015 and shares predictions on gold, the Dow, IBM and more.
CNBC
Pacific Ethanol to buy Aventine for $190 million in stock
Deal would make company the fifth-largest ethanol producer in the U.S.
MarketWatch31 mins ago
Lockheed Wins F-22 Modification Contract Worth $67.8M - Analyst Blog
Lockheed Martin (LMT) won a modification contract worth $67.8 million from the U.S. Air Force for providing services on the F-22 aircraft.
Zacks
LMT $195.22 -0.11%
Press Releases
Tekmira Establishes Manufacturing and Clinical Trial Agreement to Provide TKM-Ebola-Guinea for Clinical Studies in West Africa
Tekmira Receives Clearance to Conduct a Phase I Clinical Study With TKM-HBV
Tekmira Pharmaceuticals Announces Leadership Changes
More Press Release for Tekmira Pharmaceuticals Corporation
Related Quotes
TKM.TO17.32+7.51%
Tekmira Pharmaceuticals Corpor … Watchlist
17.32+1.21(7.51%)
Toronto9:53 AM EST
Tekmira gains on UK Ebola case
Financial Times q 20 hrs ago
Tekmira to supply Ebola treatment for studies in West Africa
Reuters 8 days ago
More
KFZ-Werkzeuge stark reduziert!
Sponsored www.zorotools.de
Rates
Must Reads
Yahoo Finance
3 key questions for McDonald's in 2015
Yahoo Finance
Apple wins Christmas with 51% of new device activations
Yahoo Finance
College to get cheaper for middle-class families
Yahoo Finance
The iPhone mafia: What happens to your stolen smartphone
Yahoo Finance
The biggest surprise for tech investors in 2014 won't come again next year
Hot Stock Minute
Will investors love Shake Shack...or shake it off?
Yahoo Finance
Should you buy Facebook?
Talking Numbers
IBM is doing something no Dow stock has done since 1995
More Top News »
More Market News
Markets in Review: Winners and Losers in 2014
Art Cashin's year-end market message CNBC Videos
North Dakota Town 'dodged A Bullet' In Crude Explosion, …
Amazon Reigns Supreme in E-Commerce as New Competitors …
Poll
With the Nasdaq about 5% away from all-time highs, which sector is best poised to lead the way higher?
28 days remaining
Healthcare
Tech
Energy
See Results
Copyright © 2014 <a href="http://www.globenewswire.com/">GlobeNewswire</a>. All rights reserved. Redistribution of this content is expressly prohibited without prior written consent. GlobeNewswire makes no claims concerning the accuracy or validity of the information, and shall not be held liable for any errors, delays, omissions or use thereof.
Data Disclaimer
Help / Suggestions
Privacy
About Our Ads
Terms
Tekmira Pharmaceuticals Corp. (TKMR) Is Accelerating To The Upside
By RTT News, December 31, 2014, 10:02:00 AM EDT
A A A
Vote up
More Sharing ServicesShare | Share on facebook Share on twitter Share on email Share on jappy Subscribe
(RTTNews.com) - Tekmira Pharmaceuticals Corp. (
TKMR
) provided an update on its Phase I/II study of TKM-PLK1 in patients with advanced Gastrointestinal Neuroendocrine Tumors and Adrenocortical Carcinoma Wednesday morning. The Company stated that it continues to see evidence of anti-tumor activity in some treated subjects, including one patient with an almost complete resolution.
Tekmira Pharmaceuticals has been rising sharply since the open of trade Wednesday and is now up 1.65 at $15.55. Trading volume has begun to accelerate in the last few minutes. The stock has climbed to a 2 1/2 week high.
For comments and feedback: contact editorial@rttnews.com
Read more: http://www.nasdaq.com/article/tekmira-pharmaceuticals-corp-t…
By RTT News, December 31, 2014, 10:02:00 AM EDT
A A A
Vote up
More Sharing ServicesShare | Share on facebook Share on twitter Share on email Share on jappy Subscribe
(RTTNews.com) - Tekmira Pharmaceuticals Corp. (
TKMR
) provided an update on its Phase I/II study of TKM-PLK1 in patients with advanced Gastrointestinal Neuroendocrine Tumors and Adrenocortical Carcinoma Wednesday morning. The Company stated that it continues to see evidence of anti-tumor activity in some treated subjects, including one patient with an almost complete resolution.
Tekmira Pharmaceuticals has been rising sharply since the open of trade Wednesday and is now up 1.65 at $15.55. Trading volume has begun to accelerate in the last few minutes. The stock has climbed to a 2 1/2 week high.
For comments and feedback: contact editorial@rttnews.com
Read more: http://www.nasdaq.com/article/tekmira-pharmaceuticals-corp-t…
Antwort auf Beitrag Nr.: 48.673.007 von blue-moon am 31.12.14 15:46:31hier mal ein Schmankerl zum Jahreswechsel
Antwort auf Beitrag Nr.: 48.649.721 von waxweazle am 26.12.14 14:16:09
Danke - man sieht sehr schön, dass hier einige Schätze schlummern, bzw. jeder Zeit gehoben werden können.
Tolle Übersicht - riesen Potntial!
Zitat von waxweazle: die pipeline sieht sehr vielversprechend aus
Danke - man sieht sehr schön, dass hier einige Schätze schlummern, bzw. jeder Zeit gehoben werden können.
Antwort auf Beitrag Nr.: 48.672.650 von Boersenbommel am 31.12.14 14:34:28News im Anflug!!!
Und ein erfolgreiches 2015 an alle
Und ein erfolgreiches 2015 an alle
Durchsuchen
ARBUTUS BIOPHARMA CORP. REGISTERED SHARES O.N. ehem Tekmira Pharmaceuticals vor dem Durchbruch?
